- Home
- GPRK vs PHAT Comparison
GPRK vs PHAT Comparison
Compare GPRK & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRK
- PHAT
- Stock Information
- Founded
- GPRK 2002
- PHAT 2018
- Country
- GPRK Colombia
- PHAT United States
- Employees
- GPRK N/A
- PHAT N/A
- Industry
- GPRK Oil & Gas Production
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- GPRK Energy
- PHAT Health Care
- Exchange
- GPRK Nasdaq
- PHAT Nasdaq
- Market Cap
- GPRK 475.6M
- PHAT 465.0M
- IPO Year
- GPRK N/A
- PHAT 2019
- Fundamental
- Price
- GPRK $8.78
- PHAT $5.67
- Analyst Decision
- GPRK Strong Buy
- PHAT Strong Buy
- Analyst Count
- GPRK 2
- PHAT 4
- Target Price
- GPRK $12.50
- PHAT $23.00
- AVG Volume (30 Days)
- GPRK 735.6K
- PHAT 1.0M
- Earning Date
- GPRK 03-05-2025
- PHAT 03-06-2025
- Dividend Yield
- GPRK 6.71%
- PHAT N/A
- EPS Growth
- GPRK N/A
- PHAT N/A
- EPS
- GPRK 1.97
- PHAT N/A
- Revenue
- GPRK $716,838,000.00
- PHAT $26,270,000.00
- Revenue This Year
- GPRK N/A
- PHAT $7,453.23
- Revenue Next Year
- GPRK $5.27
- PHAT $226.38
- P/E Ratio
- GPRK $4.46
- PHAT N/A
- Revenue Growth
- GPRK N/A
- PHAT N/A
- 52 Week Low
- GPRK $7.24
- PHAT $5.21
- 52 Week High
- GPRK $11.72
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- GPRK 39.79
- PHAT 39.59
- Support Level
- GPRK $8.89
- PHAT $5.50
- Resistance Level
- GPRK $9.54
- PHAT $6.21
- Average True Range (ATR)
- GPRK 0.34
- PHAT 0.40
- MACD
- GPRK 0.02
- PHAT 0.07
- Stochastic Oscillator
- GPRK 3.80
- PHAT 38.69
About GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil and Argentina. The company generates revenue from the sale of crude oil, condensate and natural gas net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.